Literature DB >> 22341782

A role for granulocyte-macrophage colony-stimulating factor in the regulation of CD8(+) T cell responses to rabies virus.

Celestine N Wanjalla1, Elizabeth F Goldstein, Christoph Wirblich, Matthias J Schnell.   

Abstract

Inflammatory cytokines have a significant role in altering the innate and adaptive arms of immune responses. Here, we analyzed the effect of GM-CSF on a RABV-vaccine vector co-expressing HIV-1 Gag. To this end, we immunized mice with RABV expressing HIV-1 Gag and GM-CSF and analyzed the primary and recall CD8(+) T cell responses. We observed a statistically significant increase in antigen presenting cells (APCs) in the spleen and draining lymph nodes in response to GM-CSF. Despite the increase in APCs, the primary and memory anti HIV-1 CD8(+) T cell response was significantly lower. This was partly likely due to lower levels of proliferation in the spleen. Animals treated with GM-CSF neutralizing antibodies restored the CD8(+) T cell response. These data define a role of GM-CSF expression, in the regulation of the CD8(+) T cell immune responses against RABV and has implications in the use of GM-CSF as a molecular adjuvant in vaccine development. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22341782      PMCID: PMC3294073          DOI: 10.1016/j.virol.2012.01.025

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  46 in total

Review 1.  Tolerogenic dendritic cells.

Authors:  Ralph M Steinman; Daniel Hawiger; Michel C Nussenzweig
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

2.  Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.

Authors:  V Bronte; E Apolloni; A Cabrelle; R Ronca; P Serafini; P Zamboni; N P Restifo; P Zanovello
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

Review 3.  Exploiting dendritic cells to improve vaccine efficacy.

Authors:  Ralph M Steinman; Melissa Pope
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

4.  Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells.

Authors:  A Bukreyev; I M Belyakov; J A Berzofsky; B R Murphy; P L Collins
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

5.  Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic.

Authors:  James P McGettigan; Roger J Pomerantz; Catherine A Siler; Philip M McKenna; Heather D Foley; B Dietzschold; Matthias J Schnell
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

6.  Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation.

Authors:  E M Jaffee; R H Hruban; B Biedrzycki; D Laheru; K Schepers; P R Sauter; M Goemann; J Coleman; L Grochow; R C Donehower; K D Lillemoe; S O'Reilly; R A Abrams; D M Pardoll; J L Cameron; C J Yeo
Journal:  J Clin Oncol       Date:  2001-01-01       Impact factor: 44.544

7.  Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector.

Authors:  J P McGettigan; S Sarma; J M Orenstein; R J Pomerantz; M J Schnell
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

8.  Comparative studies of the effects of recombinant GM-CSF and GM-CSF administered via a poxvirus to enhance the concentration of antigen- presenting cells in regional lymph nodes.

Authors:  E Kass; J Parker; J Schlom; J W Greiner
Journal:  Cytokine       Date:  2000-07       Impact factor: 3.861

9.  GM-CSF transgene-based adjuvant allows the establishment of protective mucosal immunity following vaccination with inactivated Chlamydia trachomatis.

Authors:  Hang Lu; Zhou Xing; Robert C Brunham
Journal:  J Immunol       Date:  2002-12-01       Impact factor: 5.422

10.  Selective induction of dendritic cells using granulocyte macrophage-colony stimulating factor, but not fms-like tyrosine kinase receptor 3-ligand, activates thyroglobulin-specific CD4+/CD25+ T cells and suppresses experimental autoimmune thyroiditis.

Authors:  Chenthamarakshan Vasu; Rukiye-Nazan E Dogan; Mark J Holterman; Bellur S Prabhakar
Journal:  J Immunol       Date:  2003-06-01       Impact factor: 5.422

View more
  7 in total

1.  Viral vectored granulocyte-macrophage colony stimulating factor inhibits vaccine protection in an SIV challenge model: protection correlates with neutralizing antibody.

Authors:  John B Schell; Kapil Bahl; Nina F Rose; Linda Buonocore; Meredith Hunter; Preston A Marx; Celia C LaBranche; David C Montefiori; John K Rose
Journal:  Vaccine       Date:  2012-04-23       Impact factor: 3.641

2.  Rabies virus is recognized by the NLRP3 inflammasome and activates interleukin-1β release in murine dendritic cells.

Authors:  Tessa M Lawrence; Andrew W Hudacek; Marcel R de Zoete; Richard A Flavell; Matthias J Schnell
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

3.  Transcriptional and posttranscriptional regulation of cytokine gene expression in HIV-1 antigen-specific CD8+ T cells that mediate virus inhibition.

Authors:  Tamika L Payne; Jeff Blackinton; Alyse Frisbee; Joy Pickeral; Sheetal Sawant; Nathan A Vandergrift; Stephanie A Freel; Guido Ferrari; Jack D Keene; Georgia D Tomaras
Journal:  J Virol       Date:  2014-06-04       Impact factor: 5.103

4.  Construction and in vitro evaluation of a recombinant live attenuated PRRSV expressing GM-CSF.

Authors:  Lingxue Yu; Yanjun Zhou; Yifeng Jiang; Wu Tong; Shen Yang; Fei Gao; Kang Wang; Liwei Li; Tianqi Xia; Qun Cheng; Guangzhi Tong
Journal:  Virol J       Date:  2014-11-25       Impact factor: 4.099

5.  Recombinant rabies virus expressing dog GM-CSF is an efficacious oral rabies vaccine for dogs.

Authors:  Ming Zhou; Lei Wang; Songqin Zhou; Zhao Wang; Juncheng Ruan; Lijun Tang; Ziming Jia; Min Cui; Ling Zhao; Zhen F Fu
Journal:  Oncotarget       Date:  2015-11-17

6.  Stable incorporation of GM-CSF into dissolvable microneedle patch improves skin vaccination against influenza.

Authors:  Elizabeth Q Littauer; Lisa K Mills; Nicole Brock; E Stein Esser; Andrey Romanyuk; Joanna A Pulit-Penaloza; Elena V Vassilieva; Jacob T Beaver; Olivia Antao; Florian Krammer; Richard W Compans; Mark R Prausnitz; Ioanna Skountzou
Journal:  J Control Release       Date:  2018-02-26       Impact factor: 9.776

7.  Transgenic sickle cell disease mice have high mortality and dysregulated immune responses after vaccination.

Authors:  Steven M Szczepanek; Eric R Secor; Sonali J Bracken; Linda Guernsey; Ektor Rafti; Adam Matson; Roger S Thrall; Biree Andemariam
Journal:  Pediatr Res       Date:  2013-05-31       Impact factor: 3.756

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.